| Summary: | Transdermal flunixin meglumine was approved in 2018 to treat pain related to foot-rot in cattle, leading to the question of whether it would be effective as part of a comprehensive pain management strategy for disbudding. To investigate, calves were assigned to three treatment groups: 2% lidocaine cornual nerve block only (L), lidocaine nerve block +0.45 mg/lb (1 mg/kg) oral meloxicam (M), or lidocaine nerve block +1.5 mg/lb (3.3 mg/kg) transdermal flunixin meglumine (F) (<i>n</i> = 61). Ear flicking (<i>p</i> = 0.001), head shaking (<i>p</i> < 0.001), tail flicking (<i>p</i> < 0.001), interaction with the environment (<i>p</i> < 0.001), grooming (<i>p</i> < 0.01), posture changes (<i>p</i> < 0.05), and standing (<i>p</i> < 0.001) were impacted by the time relative to the procedure. Cortisol levels rose post procedure (<i>p</i> < 0.001). There was no difference in rates of behaviors or cortisol between treatments. These results indicate that calves showed alterations in behavior and cortisol in response to disbudding but not between treatments. We conclude that the pain management protocol for disbudding, which included transdermal flunixin meglumine with a lidocaine cornual nerve block, did not show significant differences from protocols using meloxicam with a lidocaine block, or a lidocaine block alone.
|
|---|